Home » Newsletters » BioWorld Science

BioWorld Science

May 24, 2017

View Archived Issues

Attune reports preclinical data on ATN-249 for treatment of hereditary angioedema

MATRIX trials reveal postoperative pain reduction with bupivacaine-collagen matrix INL-001

EMA grants orphan drug designation to avacopan for C3 glomerulopathy

Churchill Pharmaceuticals submits NDA for Yonsa

United Neuroscience reports phase I data on UB-311 for Alzheimer's disease

Dose-dependent effects of intranasal oxytocin evaluated in autism spectrum disorders

Global BioLife begins research on universal therapeutic drug platform

DNAnexus partners with AstraZeneca on genomics informatics

MK-7264 shows significant efficacy in patients with refractory chronic cough

FDA grants accelerated approval to Keytruda and priority review for further indication

Imfinzi available in U.S.

GlaxoSmithKline describes novel CPHPC prodrugs

Oryx reports data on ParvOryx combination therapy in GBM

Sutter Health, Dignity Health patent podophyllotoxin and camptothecin derivatives

Calithera Biosciences presents new arginase inhibitors

OSE and Selexis sign commercial license agreement

Northwestern University patents MNK1/2 inhibitors

Palladio Biosciences acquires rights to lixivaptan

WHO Situation Report documents rise in Ebola cases/New antibodies described

Phase III study of Livatag recommended to continue

Debiopharm acquires ImmunoGen's ADC IMGN-529

Spring Bank releases initial cohort data from phase IIa study of SB-9200 in HBV

FDA and EMA accept submissions for UX-003 for mucopolysaccharidosis VII

Neurocrine reports phase II data on Ingrezza in Tourette's syndrome

FDA grants breakthrough therapy designation to plazomicin

Pierre Fabre acquires immuno-oncology assets from Igenica Biotherapeutics

A new zebrafish model of amyotrophic lateral sclerosis shows relevance of the Nefl protein

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...